Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High – Here’s Why

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $4.08 and last traded at $4.0850, with a volume of 5567772 shares trading hands. The stock had previously closed at $3.83.

Analysts Set New Price Targets

A number of research analysts have recently commented on ESPR shares. Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th. Finally, Piper Sandler started coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Esperion Therapeutics Trading Up 6.5%

The stock has a fifty day simple moving average of $3.08 and a two-hundred day simple moving average of $2.18. The firm has a market cap of $975.36 million, a PE ratio of -8.16 and a beta of 1.01.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million. As a group, sell-side analysts predict that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. grew its stake in Esperion Therapeutics by 161.1% in the 1st quarter. Invesco Ltd. now owns 255,480 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 157,647 shares in the last quarter. Two Seas Capital LP lifted its holdings in shares of Esperion Therapeutics by 43.6% during the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after acquiring an additional 3,024,104 shares during the last quarter. Graham Capital Management L.P. grew its position in Esperion Therapeutics by 153.5% in the first quarter. Graham Capital Management L.P. now owns 487,735 shares of the biopharmaceutical company’s stock worth $702,000 after acquiring an additional 295,320 shares in the last quarter. Parallel Advisors LLC increased its stake in Esperion Therapeutics by 1,174.2% in the second quarter. Parallel Advisors LLC now owns 127,424 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 117,424 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Esperion Therapeutics during the first quarter valued at about $4,446,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.